Recce Pharmaceuticals Announces Multiple Patients Dosed with RECCE® 327 in Topical Phase I/II Clinical Trial for the Treatment of Infected Burn Wounds
12 juil. 2021 08h00 HE
|
Recce Pharmaceuticals
Highlights: Multiple patients dosed in Phase I/II clinical trial, an important human clinical milestoneNo adverse symptoms reported - R327 well stocked in hospital pharmacy for further patient...
Recce Pharmaceuticals to Present at World Microbe Forum
21 juin 2021 08h00 HE
|
Recce Pharmaceuticals
SYDNEY, Australia, June 21, 2021 (GLOBE NEWSWIRE) -- Recce Pharmaceuticals Ltd (ASX:RCE) (FSE:R9Q) (Company), the Company developing new classes of synthetic anti-infectives, has accepted an...
Recce Pharmaceuticals Announces Lead Synthetic Anti-infective RECCE® 327 Demonstrates World First Multiple Mechanisms of Action against E. coli bacteria
01 juin 2021 08h00 HE
|
Recce Pharmaceuticals
Highlights: RECCE® 327 (R327) Mechanism of Action ‘unlike that of any antibiotic seen before’ with multiple mechanisms identified in independent study - to be presented at upcoming World Microbe...
Recce Pharmaceuticals Announces Lead Synthetic Anti-infective RECCE® 327 Progresses to Stage 2 of SARS-CoV-2 Antiviral Screening Program at CSIRO
20 mai 2021 10h12 HE
|
Recce Pharmaceuticals
Summary: Further study completed at the Doherty Institute as part of SARS-CoV-2 Antiviral Screening Program calculates IC50 of RECCE® 327 (R327) to be 2,046 PPM and the CC50 for R327 to be 5108...
Recce Pharmaceuticals Announces Positive Data on Bactericidal Activity of RECCE® 327 Against All Six ESKAPE Pathogens
04 mai 2021 08h00 HE
|
Recce Pharmaceuticals
Highlights: More than 99.9% effective against full suite of ESKAPE pathogens, within hours of exposure to RECCE® 327 (R327) in independent bacterial efficacy studiesR327 remains effective against...
Recce Pharmaceuticals Announces Positive Data Against Streptococcus pneumoniae Sinusitis Infection in Animal Model
01 avr. 2021 08h00 HE
|
Recce Pharmaceuticals
Highlights: Positive sinusitis infection data indicated in animal study Study supports broad spectrum potential of Recce’s anti-infective compounds against Streptococcus pneumoniae (S. pneumoniae)...
Recce Pharmaceuticals Announces The Pew Charitable Trusts' Addition of Recce’s Lead Compound RECCE® 327 to List of Antibiotic Treatments in Clinical Development
15 mars 2021 08h00 HE
|
Recce Pharmaceuticals
Highlights: RECCE® 327 included in The Pew Charitable Trusts’ annual assessment of non-traditional antibiotic treatment in clinical developmentRECCE® 327 is the only synthetic polymer drug candidate...
Recce Pharmaceuticals Dual Lists on Frankfurt Stock Exchange
09 mars 2021 08h00 HE
|
Recce Pharmaceuticals
Shares now trading on major German Trading Exchanges Shares trade under code: R9QNo related capital raising - trade of existing securities with trade volume to increase on Australian Stock Exchange...
Recce Pharmaceuticals Applies for Dual Listing on FSE (Frankfurt Stock Exchange)
24 févr. 2021 08h00 HE
|
Recce Pharmaceuticals
Highlights: Broadens institutional and retail investor base across EU and enables access to additional capital markets No related capital raising - trade of existing securities with trade...
Recce Pharmaceuticals Announces Agreement with Fiona Stanley Hospital for a Phase 1/2 Clinical Trial Evaluating Topical Spray-On Antibiotic RECCE® 327 on Chronic Burn Wounds
16 févr. 2021 08h00 HE
|
Recce Pharmaceuticals
Highlights: Phase I/II trial agreement with Fiona Stanley Hospital (Burns Unit) in Perth Western AustraliaStudy led by world leading burn treatment specialistsStudy will assess safety and efficacy of...